Avastin Boosts Survival in Cervical Cancer
Survival improved in patients with difficult to treat cases of cervical cancer.
By John Gever, MedPage Today
Don't Miss This
Sign Up for OurCancer Care and PreventionNewsletter
Thanks for signing up!You might also like these other newsletters:
THURSDAY, Feb. 7, 2013 (MedPage Today) —Overall survival among patients with cervical cancer not curable with standard treatment was improved significantly when bevacizumab (Avastin) was added to either of two chemotherapy regimens, the National Cancer Institute (NCI) announced.
Median overall survival in patients treated with bevacizumab and chemotherapy in a randomized trial was 17 months, compared with 13.3 months in patients treated with chemotherapy alone, according to top-line results of an interim analysis released late Thursday in an NCI press release.
The release did not give aPvalue for the difference, but the NCI called it "highly statistically significant."
"The data safety monitoring committee overseeing the trial recommended that the results of a recent interim analysis be made public because the study had met its primary endpoint of demonstrating improved overall survival in patients who received bevacizumab," the NCI said.
More adverse effects were seen in patients receiving bevacizumab, the agency noted. The pattern was similar to that seen with bevacizumab in other settings.
No other specific results were given in the release. It said full data would be submitted for presentation at the American Society of Clinical Oncology's annual meeting, which begins May 31.
The NCI-funded trial is called GOG240 and involves 452 patients in the U.S. and Spain with recurrent, persistent, or metastatic cervical cancer that cannot be cured with standard treatments, the agency said.
Patients in the trial were assigned to four treatment arms: cisplatin plus paclitaxel (the current standard of care), topotecan plus paclitaxel, or the same two regimens with bevacizumab added. The latter drug was given at 15 mg/kg every 3 weeks until disease progression or excessive toxicity was seen.
An earlier interim analysis had found that the two chemotherapy regimens alone were equivalent, the NCI said.
Video: Safety Findings of Long-Term Bevacizumab for Patients with Ovarian Cancer
7-Minute Butt Lifting Workout
8 Signs Stress Is Making You Sick—And How To Get Healthier, Starting Today
US midterms: What they mean for the 2020 presidential race
5 Simple Styling Lessons From Kate Bosworth To Try Now
Why Fifty Shades of Grey is good for women (and their sex lives)
How to Obtain Good Customer Service and Ensure You Are Being Helped Properly
Fitness blogger teaches us to ScrewTheScales
How to Treat Chinch Bugs Without Chemicals
5 Ways To Deal With Ageism In The Workplace
Your Year Ahead Horoscopes: Scorpio
How to Cook Pasta Al Dente
5 Ways to Cut Sugar